Equities

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)126.33
  • Today's Change1.33 / 1.06%
  • Shares traded167.72k
  • 1 Year change+13.83%
  • Beta0.3354
Data delayed at least 15 minutes, as of Nov 22 2024 15:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy9
Outperform15
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 25 analysts offering 12 month price targets for Neurocrine Biosciences, Inc. have a median target of 165.00, with a high estimate of 192.00 and a low estimate of 121.00. The median estimate represents a 32.00% increase from the last price of 125.00.
High53.6%192.00
Med32.0%165.00
Low-3.2%121.00

Earnings history & estimates in USD

On Oct 30, 2024, Neurocrine Biosciences, Inc. reported 3rd quarter 2024 earnings of 1.24 per share.
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+37.90%
Neurocrine Biosciences, Inc. reported annual 2023 earnings of 2.47 per share on Feb 07, 2024.
Average growth rate+254.17%
More ▼

Revenue history & estimates in USD

Neurocrine Biosciences, Inc. had 3rd quarter 2024 revenues of 622.10m. This bettered the 600.63m consensus of the 24 analysts covering the company. This was 47.98% above the prior year's 3rd quarter results.
Average growth rate+5.81%
Neurocrine Biosciences, Inc. had revenues for the full year 2023 of 1.89bn. This was 26.76% above the prior year's results.
Average growth rate+24.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.